Skip to content

Study · Not a test of the peptide alone · 2019

2 results

The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity.

Tałałaj U, Uścinowicz P, Bruzgo I, Surażyński A, Zaręba I, Markowska A

Molecules (Basel, Switzerland)15 Oct 2019Cited by 15 (Europe PMC)

PMID31618846 (opens in a new tab)PMCIDPMC6832239 (opens in a new tab)DOI10.3390/molecules24203698 (opens in a new tab)PepBankPUB-31618846
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

KTTKS is a matrikine that originates from the proteolytic hydrolysis of collagen. This peptide stimulates ECM production and types I and III collagen expression in vitro. A more stable form of KTTKS is pal-KTTKS, known as Matrixyl® or palmitoyl pentapeptide-3. A series of novel pentapeptides, analogues of KTTKS with the general formula X-KTTKS-OH(NH2), where X = acetyl, lipoyl, palmitoyl residues, was designed and synthesized. Their effect on amidolytic activity of urokinase, thrombin, trypsin, plasmin, t-PA, and kallikrein were tested. Cytotoxic tests on fibroblasts, as well as collagen and DNA biosynthesis tests for selected peptides, were also carried out. The test results showed that the most active plasmin inhibitors were palmitoyl peptides, whether in acid or amide form. No biological effects of lysine modification to arginine in the synthesized peptides were found. None of the synthesized peptides was not cytotoxic on fibroblasts, and three of them showed cell growth. These three compounds showed no concentration-activity relationship in the collagen and DNA biosynthesis assays.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  1. 01LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cells)Safety outcome

    In fibroblasts, the abstract reports pooled cytotoxicity results for synthesized peptides with an ambiguous double negative.

    In plain wordsIn cells, the pooled peptide cytotoxicity result is unclear because the source uses a double negative.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    Direction not reportedFibroblast cytotoxicity
    Study

    n: not reported in source

    Fibroblasts
    Outcome group
    Adverse events · Pharmacology

    Source sentences

    Summary
    None of the synthesized peptides was not cytotoxic on fibroblasts, and three of them showed cell growth.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

  2. 02LabNot a test of Matrixyl (palmitoyl pentapeptide-4) aloneIn vitro (cell-free)Activity measurement

    In protease assays, palmitoyl peptides pooled across acid and amide forms were the most active plasmin inhibitors.

    In plain wordsIn lab tests, pooled palmitoyl peptides inhibited plasmin most strongly among the synthesized peptides.

    Peptide
    Matrixyl (palmitoyl pentapeptide-4)
    Outcome
    IncreasePlasmin inhibition
    Study

    n: not reported in source

    Protease assays
    Comparator
    Other synthesized peptides
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The test results showed that the most active plasmin inhibitors were palmitoyl peptides, whether in acid or amide form.

    In this study, Matrixyl (palmitoyl pentapeptide-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Matrixyl (palmitoyl pentapeptide-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.